EA201590918A1 - Антитела к bmp-6 - Google Patents

Антитела к bmp-6

Info

Publication number
EA201590918A1
EA201590918A1 EA201590918A EA201590918A EA201590918A1 EA 201590918 A1 EA201590918 A1 EA 201590918A1 EA 201590918 A EA201590918 A EA 201590918A EA 201590918 A EA201590918 A EA 201590918A EA 201590918 A1 EA201590918 A1 EA 201590918A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
bmp
antigen binding
binding fragments
bind
Prior art date
Application number
EA201590918A
Other languages
English (en)
Inventor
Стефани Мари Итон Трухлар
Неунгсеон Сео
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49918813&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201590918A1 publication Critical patent/EA201590918A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Настоящее изобретение относится к антителам или их антигенсвязывающим фрагментам, которые связываются с ВМР-6 человека, композициям, содержащим такие антитела или их антигенсвязывающие фрагменты, и способам их применения для лечения анемии хронического заболевания.
EA201590918A 2012-12-17 2013-12-05 Антитела к bmp-6 EA201590918A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737859P 2012-12-17 2012-12-17
PCT/US2013/073239 WO2014099391A1 (en) 2012-12-17 2013-12-05 Bmp-6 antibodies

Publications (1)

Publication Number Publication Date
EA201590918A1 true EA201590918A1 (ru) 2015-10-30

Family

ID=49918813

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590918A EA201590918A1 (ru) 2012-12-17 2013-12-05 Антитела к bmp-6

Country Status (34)

Country Link
US (2) US8795665B2 (ru)
EP (1) EP2931748B1 (ru)
JP (1) JP6033459B2 (ru)
KR (1) KR20150083918A (ru)
CN (1) CN104870473B (ru)
AP (1) AP2015008600A0 (ru)
AR (1) AR093620A1 (ru)
AU (1) AU2013363548A1 (ru)
BR (1) BR112015012708A2 (ru)
CA (1) CA2892911C (ru)
CL (1) CL2015001639A1 (ru)
CY (1) CY1118254T1 (ru)
DK (1) DK2931748T3 (ru)
EA (1) EA201590918A1 (ru)
ES (1) ES2608381T3 (ru)
HK (1) HK1209763A1 (ru)
HR (1) HRP20161587T1 (ru)
HU (1) HUE032431T2 (ru)
IL (1) IL239242A0 (ru)
LT (1) LT2931748T (ru)
MA (1) MA38161A1 (ru)
ME (1) ME02515B (ru)
MX (1) MX2015007831A (ru)
PE (1) PE20151164A1 (ru)
PH (1) PH12015501360A1 (ru)
PL (1) PL2931748T3 (ru)
PT (1) PT2931748T (ru)
RS (1) RS55413B1 (ru)
SG (1) SG11201504695QA (ru)
SI (1) SI2931748T1 (ru)
TN (1) TN2015000277A1 (ru)
TW (1) TW201439118A (ru)
WO (1) WO2014099391A1 (ru)
ZA (1) ZA201504282B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
CA3027651A1 (en) * 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
MA56203A (fr) * 2019-06-12 2022-04-20 Regeneron Pharma Anticorps humains dirigés contre la protéine morphogénétique osseuse 6
JP2023520969A (ja) * 2020-04-07 2023-05-23 マブウェル セラピューティクス インコーポレイテッド 抗ｔｍｐｒｓｓ６抗体及びその用途
CN114075287B (zh) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077006A1 (en) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
EP1858541B1 (en) 2005-02-16 2012-07-25 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency
AU2009313902B9 (en) * 2008-11-13 2014-03-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
US20110070242A1 (en) 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6

Also Published As

Publication number Publication date
BR112015012708A2 (pt) 2017-09-12
SI2931748T1 (sl) 2017-01-31
LT2931748T (lt) 2017-01-10
JP6033459B2 (ja) 2016-11-30
AP2015008600A0 (en) 2015-07-31
CA2892911C (en) 2017-02-28
JP2016501273A (ja) 2016-01-18
US20140170161A1 (en) 2014-06-19
TN2015000277A1 (en) 2016-10-03
CL2015001639A1 (es) 2015-10-02
MX2015007831A (es) 2015-08-20
CY1118254T1 (el) 2017-06-28
AU2013363548A1 (en) 2015-05-28
PH12015501360A1 (en) 2015-09-02
SG11201504695QA (en) 2015-07-30
DK2931748T3 (da) 2017-01-02
HUE032431T2 (en) 2017-09-28
CN104870473B (zh) 2018-05-29
HRP20161587T1 (hr) 2017-01-13
PT2931748T (pt) 2016-11-02
US8795665B2 (en) 2014-08-05
EP2931748B1 (en) 2016-10-05
HK1209763A1 (zh) 2016-04-08
PL2931748T3 (pl) 2017-05-31
KR20150083918A (ko) 2015-07-20
RS55413B1 (sr) 2017-04-28
MA38161A1 (fr) 2017-12-29
CA2892911A1 (en) 2014-06-26
WO2014099391A1 (en) 2014-06-26
US20140309404A1 (en) 2014-10-16
PE20151164A1 (es) 2015-08-19
CN104870473A (zh) 2015-08-26
AR093620A1 (es) 2015-06-10
EP2931748A1 (en) 2015-10-21
ES2608381T3 (es) 2017-04-10
ME02515B (me) 2017-02-20
IL239242A0 (en) 2015-07-30
ZA201504282B (en) 2017-11-29
TW201439118A (zh) 2014-10-16
US8980582B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
CY1122278T1 (el) Αντι il-36r αντισωματα
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
EA201590918A1 (ru) Антитела к bmp-6
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
CY1122978T1 (el) Αντισωματα εναντι-vla-4
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
BR112014019611A2 (pt) agentes de ligação mica
EA201492101A1 (ru) Антитела против fcrn
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201791393A3 (ru) Антитела к erbb3 и их применение
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201690064A1 (ru) Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EA201890434A1 (ru) Антитела к cd154 и способы их применения